Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV
IDEAL STUDY

Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin
IDEAL Study: Design

- **Study**
  - Randomized comparative trial
  - 118 centers in United States

- **Subjects**
  - N = 3070 with chronic hepatitis C
  - All genotype 1 (other genotypes excluded)
  - Treatment naïve
  - Subjects were 18 years of age or older

- **Regimens (Ribavirin Dosed by Weight)**
  - Peginterferon alfa-2b: 1.5 µg/kg 1x/week + Ribavirin 800-1400 mg/day*
  - Peginterferon alfa-2b: 1.0 µg/kg 1x/week + Ribavirin 800-1400 mg/day*
  - Peginterferon alfa-2a: 180 µg 1x/week + Ribavirin 1000-1200 mg/day^

- **Primary Endpoint (Sustained Virologic Response [SVR])**
  - SVR = Undetectable serum HCV RNA 24 weeks after 48-week treatments

*Ribavirin dosing: 40-65 kg: 800 mg/d; >65-85 kg: 1000 mg/d; >85-105 kg: 1200 mg/d; >105-120 kg: 1400 mg/d
^Ribavirin dosing: < 75 kg: 1000 mg/d; ≥75 kg: 1200 mg/d

Peginterferon alfa-2b + Ribavirin vs Peginterferon alfa-2a + Ribavirin

IDEAL Study: Results

IDEAL Study: Virologic Responses by Treatment Regimen

Peginterferon alfa-2b + Ribavirin vs Interferon alfa-2a + Ribavirin

IDEAL Study: Results

IDEAL Study: Serious Adverse Event Rates

Conclusions: “In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between the two available peginterferon-ribavirin regimens or between the two doses of peginterferon alfa-2b.”

This slide deck is from the University of Washington’s *Hepatitis C Online* and *Hepatitis Web Study* projects.

**Hepatitis C Online**
www.hepatitisc.uw.edu

**Hepatitis Web Study**
http://depts.washington.edu/hepstudy/

Funded by a grant from the Centers for Disease Control and Prevention.